news, journals and articles from all over the world.
Investigators at Cedars-Sinai and other institutions conducted a nationwide, population-based study to identify trends in the use of glucagon-like peptide-1 receptor agonists (GLP-1RAs)—prescription medications sold under popular drug names like Ozempic and Wegovy—in the United States.
Weight-loss drugs are all over the news these days. A Penn State Health expert helps separate fact from fiction and determine what’s the safest alterative for the people who need them.
A new study by researchers at the Case Western Reserve University School of Medicine reveals that the popular diabetes and weight-loss drugs Wegovy and Ozempic are linked to reduced incidence and recurrence of alcohol abuse or dependence.
Public interest in weight loss drugs like Wegovy and Ozempic is surging, but national data on dispensing patterns in the United States are surprisingly scarce.
New weight-loss drugs have helped people with their diabetes, obesity, even high blood pressure. But how they affect our mental health is a much more complicated issue, says Dr. Carrie McAdams, a psychiatrist and eating disorders expert at UT Southwestern…
Over the last year, prescriptions for medications that can accelerate weight loss in people with diabetes, or without it, have skyrocketed. But how can these weight loss medications affect the heart? A preventive cardiologist shares how this shifting landscape might affect cardiovascular care and how he advises his patients.
More than 37 million Americans have been diagnosed with diabetes, with another 8.5 million believed to be living with the condition undiagnosed. In addition, 38 percent of the United States adult population is estimated to have prediabetes, a serious condition…
A new drug encourages weight loss and increases endurance by making the body act like it is exercising.
A team of clinicians, exercise scientists, pharmaceutical scholars, ethicists, and behavioral experts at the University of California, Irvine, outlined their concerns that the use of glucagon-like peptide-1 receptor agonists (GLP-1RA’s) to treat childhood obesity and type 2 diabetes may have unintended and adverse consequences for children’s health.
The science is unclear on exactly why an increasingly popular new class of federally approved diabetes and obesity medications work, but they do know that they are effective at helping people lose weight.
With the growing popularity of medications like Ozempic® (semaglutide), Trulicity® (dulaglutide), and other glucagon-like peptide-1 (GLP-1) receptor agonists for the treatment of type 2 diabetes and weight loss, the American Society of Anesthesiologists (ASA) suggests withholding the medication before elective surgery to reduce the risk of complications associated with anesthesia in adults and children.
English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
Urdu